- New data from Immutep (IMM) is scheduled to be presented in three poster presentations during the American Society of Clinical Oncology’s 2021 Annual Meeting
- The annual meeting is the world’s largest gathering of oncology physicians, industry representatives, researchers and investment analysts, coming together to discuss clinical research and therapeutics in oncology
- At the meeting Immutep will discuss two recent clinical trials that explored the use of its lead product, known as ‘efti’, for treating cancer and infectious disease
- Immutep will also host a webcast after the meeting to discuss its data and results, and provide an update on the company’s business
- Ahead of market open, Immutep last traded at 43 cents
New data from Immutep (IMM) is scheduled to be presented in three poster presentations during the American Society of Clinical Oncology’s 2021 Annual Meeting.
Immutep is the leading developer of LAG-3 related immunotherapy treatments for cancer and autoimmune disease. The company’s lead product is eftilagimod alpha, or ‘efti’ for short, an antigen-presenting cell activator being explored in cancer and infectious disease.
Immutep’s latest data from its TACTI-002 and INSIGHT-004 studies involving efti will be presented during the online meeting from June 4 to June 8.
TACTI-002 was a phase two clinical trial that evaluated the combination of efti with the Keytruda drug in up to 183 patients with non-small cell lung cancer or head and neck squamous cell carcinoma. INSIGHT-004 was a phase one clinical trial that evaluated the safety, tolerability and recommended dose of efti when given in combination with a human antibody, avelumab, in 12 patients with solid cancers.
The annual meeting is the world largest gathering of oncology physicians, industry representatives, researchers and investment analysts, who come together to discuss cutting-edge clinical research and therapeutics in oncology, gaining insights for improving cancer care.
Immutep plans to hold a webcast after the annual meeting to discuss the data and results, as well as to provide an update on the company’s business.
Ahead of market open, Immutep last traded at 43 cents at 9:15 am AEST.